Psychopharmacology and Psychiatry Updates
von Psychopharmacology Institute
- wöchentlichErscheinungsrhythmus
- 13 mintypische Länge
- vor 2 Tagenletzte Folge
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Folgen
Prazosin for PTSD Nightmares
In this episode, we explore prazosin for PTSD-related nightmares with Dr. David Osser. He explains why prazosin stands out among alpha-1 blockers, which patients are most likely to respond, and why so many trials failed from underdosing, in
First-Episode Psychosis in Women
Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. • Learn more about our membership here • Earn 0.5 CMEs: Quick Take Vol. 87 • First-Episode Psychosis in Women: Which Antipsychotic Is the Preferred Choice?
Second-Generation Antipsychotics for OCD Augmentation
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. • Learn more about our memberships here • Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation • Second-Generation Antipsychotics for OCD Augmentation: Third-Line Agents
Are Z-Drugs Safe in the First Trimester of Pregnancy?
In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defec
Glutamatergic Augmentation in OCD
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. • Learn more about our memberships here • Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation • Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Oth
Schizophrenia: Which of Seven Antipsychotics Wins?
Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D. • Learn more about our memberships here • Earn 0.75 CMEs: Quick Take Vol. 85 • Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?
SSRI Dosing for OCD: Beyond FDA Guidelines
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. • Learn more about our memberships here • Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines • Treatment-Resistant OCD: From SSRIs to Augmentation
Trazodone for Insomnia and Comorbid Depression
In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia an
Antipsychotics, Prolactin, and Sexual Side Effects
In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term h
EMERGENT-5: Cobenfy and Treatment Durability
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side ef
Antipsychotics and Weight Gain
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emer
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explai
AUD Medications and Hepatic Safety
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to h
GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from
Gabapentin, Topiramate & Baclofen in AUD
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are
Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective
Disulfiram Unpacked: Efficacy, Risks, and Liver Safety
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced s
GLP-1s and Lithium: What Clinicians Need to Know
In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Facult
Naltrexone for Alcohol Use Disorder: What You Should Know
In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't targ
The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life
In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that
Difficult-to-Treat Depression: First, Second, and Third-Line Strategies
In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-base
Is High-Dose Olanzapine A Clozapine Alternative?
In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an option. Can pushing the dose bridge
CANMAT Guidelines: Herbs, Supplements, and Depression
In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John's wort to saffron — and how to have evidence-based, collaborative conversations with patients who p
Xylazine in the ED: Managing Toxicity
In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what clinicians need to know when naloxone simply isn't enough. Dr. David Gorelick breaks down the current
Choosing the First Step in Depression Treatment: A CANMAT Guide
In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, patient preference, and treatment availability shape your first clinical move? Dr. Sagar Parikh break
After Delirium Clears: When to Deprescribe?
In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could a medication prescribed to keep your patient safe in the short term actually be harming them months
The Clinician's Guide to Paliperidone & Risperidone LAIs
In this episode, we explore the practical dosing, initiation, and conversion strategies for paliperidone palmitate and risperidone long-acting injectables in schizophrenia. How do you manage a missed six-month injection — reload or continue
Antipsychotic Switching: Six Clinical Tips
In this episode, we explore the surprisingly thin evidence base behind antipsychotic switching — one of psychiatry's most common clinical maneuvers. Dr. Oliver Freudenreich breaks down a landmark systematic review and shares six practical t
Mastering Long-Acting Injectables: Aripiprazole & Olanzapine
In this episode, we explore the practical use of long-acting injectable antipsychotics in schizophrenia — specifically aripiprazole and olanzapine formulations. What's the right dose when a patient misses an injection? Dr. Brian Miller brea
Preventing Relapse: The Role of LAIs in Schizophrenia
In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-ma
